获取途径

作者

Shijiang Wang, Fen Zhao, Jin Wang, Ying Hua, Yongling Ji, Chaojie Wang, Li Man, Zhiye Zhang, Jun Chen, Jianbing Chen, Hongmei Li, Xuezhen Ma, Zhaohui Liang, Xianyu Meng, Jun Wang, Xiaozhi Zhang, Jinming Yu, Linlin Wang

作者单位

Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China. ³ Zhejiang Cancer Hospital, Hangzhou, China. ⁴ Henan Provincial People's Hospital, Zhengzhou, China. ⁵ Anshan Cancer Hospital, Anshan, China. ⁶ The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China. ⁷ The Affiliated People's Hospital of Ningbo University, Ningbo, China. ⁸ Heping Hospital Affiliated to Changzhi Medical College, Changzhi, China. ⁹ The Affiliated Hospital of Qingdao University, Qingdao, China. ¹⁰ Qingdao Cancer Prevention and Treatment Research Institute, Qingdao Central Hospital, University of Health and Rehabilitation Sciences (Qingdao Central Hospital), Qingdao, China. ¹¹ Yuncheng Central Hospital, Yuncheng, China. ¹² Anyang Tumor Hospital, Anyang, China. ¹³ The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. ¹⁴ The First Affiliated Hospital of Medical college, Xi'an Jiaotong University, Xi'an, China. ¹⁵ Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China. Electronic address: llwang@sdfmu.edu.cn. Affiliations ¹ Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China. ² Zhejiang Cancer Hospital, Hangzhou, China

刊名

International journal of radiation oncology, biology, physics

年份

2026

ISSN

1879-355X

关键词

cancer therapy-induced thrombocytopenia concurrent chemoradiotherapy rhTPO small-cell lung cancer.

摘要

Purpose: Concurrent chemoradiotherapy is the standard therapy for limited-stage small-cell lung cancer but induces cancer therapy-induced thrombocytopenia , which leads to treatment delays. This study aims to assess the efficacy and safety of prophylactic recombinant human thrombopoietin in preventing CTIT in this patient population. Methods and materials: This prospective, multicenter, phase II trial was conducted across 14 Chinese centers. LS-SCLC patients receiving etoposide plus cisplatin...更多

Purpose: Concurrent chemoradiotherapy is the standard therapy for limited-stage small-cell lung cancer but induces cancer therapy-induced thrombocytopenia , which leads to treatment delays. This study aims to assess the efficacy and safety of prophylactic recombinant human thrombopoietin in preventing CTIT in this patient population. Methods and materials: This prospective, multicenter, phase II trial was conducted across 14 Chinese centers. LS-SCLC patients receiving etoposide plus cisplatin or carboplatin chemotherapy with concurrent radiotherapy were given subcutaneous rhTPO on Days 1-5, 8-12, and 15-19 during radiotherapy. rhTPO treatment was stopped if platelet count reached ≥300 × 10⁹/L or increased by ≥100 × 10⁹/L from baseline. Primary endpoints were the nadir and peak platelet count. Results: From March 8, 2024, to October 10, 2024, 56 LS-SCLC patients were enrolled. During rhTPO treatment period, nadir platelet count was 128.54 ± 54.15, and peak platelet count reached 409.23 ± 173.50. Overall incidence of CTIT was 33.9% including 8.9% Grade 3 and no Grade 4-5 events. A total of 78.9% of patients experienced platelet count recovery to ≥100 × 10⁹/L during the rhTPO treatment period. Median time for platelet count recovery from <100 × 10⁹/L to ≥100 × 10⁹/L was 8 days . Multivariable logistic regression analysis revealed that low baseline platelet count was an independent risk factor for developing CTIT [OR = 4.26, 95% CI: 1.08-16.78; p = 0.038]. No patients required platelet transfusions or experienced radiotherapy interruptions, and only one patient required a reduction in the dose of chemotherapy throughout entire study. Moreover, no serious adverse events were reported. rhTPO-related adverse reactions were infrequent and predominantly Grade 1 . Conclusions: Prophylactic rhTPO during CCRT for patients with LS-SCLC demonstrated a potential benefit in maintaining platelet counts with a low incidence of CTIT. These findings support further investigation of rhTPO as a preventive strategy for high-risk CTIT patients.收起

文献类型

期刊